Hederal Hashgraph Archives

Tags archive: Hederal Hashgraph

Crypto Executives

What is Hedera Hashgraph? CEO Interview with Mance Harmon

July 2, 2018 0

Mance Harmon, the CEO of Hedera Hashgraph is interviewed by Rambler from Crypto Love. Hedera Hashgraph is a new permissionless, decentralized public ledger built on…

Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

2024-12-02T13:30:00Z

Healthy Extracts expands order after high demand for Gelteq’s collagen and Mynus sugar blocker gels

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts’ platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market.

This growing partnership supports Gelteq’s strategic push into the U.S. market following the recent hiring of Adam Bendell as the Company’s U.S. President and the establishment of a U.S.-based office. Production of Healthy Extracts’ order is underway, with shipment expected in January 2025.

“Gelteq is dedicated to delivering products offering an improved delivery platform to those who may struggle to swallow or digest traditional nutraceutical products, which we anticipate will result in improved commercial success,” Gelteq Co-Founder and CEO Nathan Givoni said. “Our partnership with Healthy Extracts is a perfect example of how our formulations can create a revolutionary and convenient way for consumers to ingest the product with the added benefits of easier digestion and better absorption. We believe the increase in demand is a testament to our innovative products and a positive step forward in our commitment to building long-term shareholder value.”

“Gelteq’s advanced technology offers a cutting-edge delivery system that empowers us to expand existing sales channels and capitalize on new market opportunities, all while delivering a more satisfying and impactful experience for consumers. This partnership is poised to drive higher margins, accelerate revenue growth, and strengthen our leadership in the rapidly expanding U.S. health and wellness market. We are confident that Gelteq's collaboration will be a pivotal factor in driving the sustained growth and success of our business,” said Duke Pitts, Healthy Extracts President.

Gelteq and the Healthy Extracts team will continue to expand the range of their partnership and expect to announce new products in early 2025.

About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.

About Healthy Extracts
Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals. The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids. UBN’s KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.

Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in the final prospectus filed on October 22, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

Contact:
CORE IR
516-222-2560
[email protected]